Sherman Matthew L's Form 4 filing
Deciphera Pharmaceuticals, Inc. (DCPH) · filed Dec 14, 2023
- Accession no.
- 0000950170-23-070382
- Filed
- Dec 14, 2023
- Trade date
- Dec 12-13, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $42.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sherman Matthew LCIK 0001325710 | Officer (EVP & Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 12, 2023 | Common Stock | AGrant or awardAcquired | +8,244 | –F1 | – | 99,306 | Direct | |
| Dec 13, 2023 | Common Stock | SSaleDisposed | −2,792 | $15.37 | −$42,913.04 | 96,514 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On December 12, 2023, the Issuer's Compensation Committee confirmed that performance criteria one had been met, resulting in the vesting of 8,244 RSUs.
Referenced by the price of 1 transaction in Table I.